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ABSTRACT 
 
Introduction: Both risperidone and venlafaxine are metabolized by Cytochrome P450 2D6 
(CYP2D6). Genetic polymorphism in this enzyme may contribute to the significant variation 
in pharmacokinetics for these substances. It has previously been shown that systemic 
exposure of risperidone and venlafaxine is increased in patients with homozygous mutations 
in CYP2D6 (poor metabolizers). The possible influence of heterozygous mutations in 
CYP2D6 on systemic exposure is not well investigated for these drugs. 
Aim: The aim of the present analysis was to investigate the importance of heterozygous 
mutations in CYP2D6 for serum concentrations of venlafaxine and risperidone and their main 
metabolites. 
Method: Data were collected from a therapeutic drug monitoring database at the Department 
of Psychopharmacology at Diakonhjemmet Hospital. The patient samples were requested as a 
part of follow-ups and control of drug treatment. Steady-state serum concentrations of parent 
compound and metabolite as well as CYP2D6, CYP2C9 and CYP2C19 genotypes were 
collected for all patients. For risperidone, both tablets and long-acting injection were included 
in this analysis. 
Result: The present analysis showed that heterozygous extensive metabolizers (n=23) had 
significantly higher (p<0.01) concentration/dose ratio of risperidone compared to CYP2D6 
extensive metabolizers (n=42) after administration of risperidone tablets. Extensive 
metabilizers (n=32) on risperidone long-acting injection had significantly higher ratio of 9-
hydroxyrisperidone and risperidone (p<0.03) compared to heterozygous extensive 
metabolizers (n=12) for 9-hydroxyrisperidone/risperidone ratio. CYP2D6 extensive 
metabolizers on venlafaxine (n=52) had significantly higher levels of O-desmethylvenlafaxine 
(p<0.02) and O-desmethylvenlafaxine/venlafaxine ratio (p<0.01) compared to CYP2D6 
heterozygous extensive metabolizers (n=41). Concentration/dose ratio of N- 
desmethylvenlafaxine was significantly higher (9-fold higher) (p<0.01) in CYP2D6 
heterozygous extensive metabolizers (n=6) compared to CYP2D6 extensive metabolizers 
(n=13). 
Conclusion: Common for risperidone and venlafaxine is that even though the sum of the 
active moiety not is changed, the relative contribution of parent compund and active 
metabolite to the sum is altered. It is the sum of the active moiety that is determined in 
therapeutic drug monitoring, and patients with different CYP2D6 genotypes are therefore 
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treated equally in clinical practice as the sum will be the same independent of genotype. This 
could be a problem if there is a difference in effect and/or adverse drug reactions mediated by 
parent drug and metabolite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 -  - 8
 
1. INTRODUCTION 
 
1.1 Variation in drug response 
 
The response to given dose of a drug may vary significantly between two persons who are 
given the same dose of drug. Variation in drug response may be caused by variation in 
pharmacokinetics and/or pharmacodynamics. This variation may be genetically, 
physiologically, pathophysiologically or environmentally influenced (Eichelbaum et al, 
2006). Genetic factors may account for as much as 95% of interindividual differences in 
serum concentration of drugs (Kalow et al, 1998). Examples of factors which may potentially 
affect systemic exposure of drugs are age, weight, organ function, interactions with other 
drugs, pregnancy, smoking and diet.  
 
1.2 CYP enzyme system 
 
An important contributor to variation in drug response is variation in drug metabolism. The 
cytochrome P-450 (CYP) enzyme is a group of enzymes that change substances to more 
hydrophilic metabolites which are more easily eliminated from the body. The role of CYP-
enzymes is to detoxify foreign substances, including many drugs. The most important CYP-
enzymes in the metabolism of psychotropic drugs are CYP1A2, CYP2C9, CYP2C19, 
CYP2D6 and CYP3A4 (Dahl, M. L., 2002). CYP2D6, CYP2C9 and CYP2C19 show genetic 
polymorfism and for these enzymes a total lack of and/or reduced enzyme activities have been 
identified (Table 1.1). For CYP2D6 and CYP2C19, mutations that results in increased 
enzyme activity have also been detected. 
 
The different genotypes will give different drug exposure and thereby unpredictable risk for 
side effects and failure of therapy. Poor metabolizers (PM) have inactivating mutations in 
both gene copies and therefore do not produce active enzyme. Standard dosing with a drug 
that is mainly metabolized by this enzyme often results in higher serum concentrations than 
expected according to dose, and thereby increased risk of overdose and side effects. PM 
should therefore be treated with lower dose than what is normal for the drug, as long as it is 
the drug that is pharmacologic active, and not the metabolite. Approximately 7 % of 
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Caucasians are CYP2D6 PM (Dahl et al, 1995). Heterozygote extensive metabolizers (HEM) 
have inactivating mutation in one gene copy and one gene copy that produces fully active 
enzyme. The result of heterozygote mutations may be an intermediate metabolic capacity, and 
therefore HEM may risk higher serum concentrations than what is expected in proportion to 
dose. Homozygote extensive metabolizers (EM) have no mutations and therefore have two 
gene copies that can produce fully active enzyme (wild type). Ultra rapid metabolizers (UM) 
have more than two gene copies and metabolize drugs by CYP2D6 faster than EM. The 
overall frequency of the amplified CYP2D6-allele is about 1% in Caucasians (Dahl et al, 
1995). Risk for failure of drug therapy is high when treating UM with standard doses of drugs 
that are metabolized by CYP2D6, if it is the drug, and not the metabolite that is active. The 
clinical importance of mutations is dependent on the relative importance of the mutated CYP 
enzyme for the elimination of the drug as well as the capacity in alternative eliminating 
pathways. 
 
1.3 Therapeutic drug monitoring (TDM) 
 
Serum concentration measurement is an important tool in order to minimize adverse drug 
reactions and optimize therapeutic response. Serum concentration measurement is important 
in psychiatry because many psychotrophic drugs are metabolized by CYP2D6 and in addition 
many psychiatric patients have poor compliance. The use of serum concentration 
measurement is especially indicated for drugs with a small therapeutic range, for drugs with 
well documented relation between concentration and effect and/or side effects, and for drugs 
with a wide pharmacokinetic variability (Rudberg et al, 2005). Especially some groups of 
patients can benefit from TDM, for instance the elderly, children, breast-feeding women and 
pregnant women, patients using multiple drugs, patients with poor compliance, and patients 
with decreased organ function (Rudberg et al, 2005).  
 
1.4 CYP-genotyping 
 
Genotyping of CYP-enzymes is useful when the patient is using a drug which has serum 
concentration that in a high degree is determined by the genotype of a CYP enzyme. CYP-
genotyping would be an advantage before starting with some drugs, for instance warfarin that 
is metabolized by CYP2C9, as serum concentration related side-effects of warfarin might 
have a fatal outcome (Wadelius and Pirmohamed, 2006). Other reasons given for CYP-
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genotyping are failure of therapy and/or side-effects in patients that already have been 
medicated with the drugs (Rudberg et al, 2005). If genotyping was performed before the 
patients were medicated, precautions, like for instance adjusted drug dosage or a change of 
medicine, could have been taken. 
 
Table 1.1 An overview of the most mutations in CYP2D6, CYP2C9 and CYP2C19. 
Enzyme Mutation                                                 Enzyme activity 
Allele 
frequency in 
Caucasians 
CYP2C9  *2: Amino acid change R144C, 430C>T  Reduced  11 % 1 
 *3: Amino acid change I359L, 1075A>C        Reduced 9 % 1 
 *5:  Amino acid change D360E, 1080C>G Reduced Rare 2 
CYP2C19 *2: Splice defect 681G>A None 15 % 3 
 *3:Stopcodon 636G>A None 8,3 % 3 
 *4:GTG initial codon 1A>G None Rare 4 
 *5: Amino acid change R433W, 1297C>T None < 0,9 %4 
 *17: Amino acid change 806C>T, 3402C>T Increased 18%5 
CYP2D6 *2: Duplication of CYP2D6 gene Increased 1-2 % 6,7 
 *3: Readingframe change 2549A>del None 2,7 % 8 
 *4: Splice defect 1846G>A None 21,5-28,6 % 8 
 *5: Deletion of CYP2D6 gene None 3 % 8 
 *6: Readingframe change 1707T>del None 1 % 7 
 *7: Amino acid change H324P, 2935A>C None Rare 8 
 *8: Stop codon 1758G>T None Rare 8 
 *9: Base-pair deletion 2613_2615delAGA Reduced 1-2%7 
 *10: Amino acid change 100C>T Reduced <2%7 
 
*17:Amino acid change 1111C>T, 2938C>T , 
4268G>C Reduced Rare7 
1 Scordo et al, 2001, 2Yasar et al, 2002, 3Jose et al, 2004, 4Ibenau et al, 1998, 5Sim et al, 2005 6Dahl et al,1995, 
7Bradford, 2002, 8Zackrisson et al, 2003 
 
1.5 Risperidone 
 
Risperidone is the active substance in the atypical antipsychotic drug Risperdal® which 
inhibits dopaminerg and serotonerg transmission in the central nervous system (CNS). 
(Leysen et al, 1988). Risperidone is administered as tablets, long-lasting injection (Risperdal 
Consta®), mixture and melting tablets. Risperidone tablets are dosed 1-2 times daily. 
Risperidone injection is an option for the maintenance therapy of schizophrenia and with 
repeated injections every two weeks, steady state levels are usually reached after three 
injections (Knox et al, 2004). Patients receiving risperidone long-acting injection has 
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significant lower serum concentrations of risperidone and its main metabolite 9-
hydroxyrisperidone than patients taking equivalent doses oral risperidone. Patients receiving 
risperidone long-lasting injection also have lower 9-hydroxyrisperidone/risperidone ratio than 
patients taking oral risperidone (Nesvåg et al, 2006).  
 
Risperidone is metabolized mainly by CYP2D6 to the pharmacologically active 9-
hydroxyrisperidone, but also CYP3A enzymes are found to be involved in the metabolism of 
risperidone to 9-hydroxyrisperidone (Fang et al, 1999) (Figure 1.1). An in vitro study has 
shown that intrinsic clearence (Clint) for risperidone was about 20 times higher for CYP2D6 
than for CYP3A4 (Fang et al, 1999). Terminal half life for risperidone is about 6-7 hours, and 
for 9-hydroxyrisperidone about 24 hours (Riedel et al, 2004). The sum of risperidone and 9-
hydroxyrisperidone form the active moiety in vivo. In TDM, the two compounds are 
summarized, following Consensus Guidelines (Baumann et al, 2004).  
 
Genetic polymorphism has been shown to be an important contribution to pharmacokinetic 
variability of risperidone (Aravagiri et al, 2003). CYP2D6 PM has significantly higher serum 
concentration of risperidone compared to CYP2D6 EM after administration of risperidone 
tablets (Mihara et al, 2003, Scordo et al, 1999), as well as an increased risk of side-effects (de 
Leon et al, 2005). In addition, Scordo and co-workers showed that for patients on risperidone 
tablets, CYP2D6 HEM had significantly higher ratios of risperidone/9-hydroxyrisperidone 
compared to CYP2D6 EM, while there were no significant differences between the two 
groups for the C/D ratio of the risperidone, C/D ratio of 9-hydroxyrisperidone or C/D ratio of 
the active moiety (Scordo et al, 1999). The same was also seen in another study (Riedel et al, 
2005). For risperidone long acting injection, there are no investigations on the significance of 
CYP2D6 genotype for serum concentration of risperidone and 9-hydroxyrisperidone. 
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Figure 1.1 Metabolism of risperidone by CYP2D6 and CYP3A4.  
 
1.6 Venlafaxine 
 
Venlafaxine, the active substance in the antidepressant Efexor®, inhibits reuptake of serotonin 
and noradrenalin in CNS (Muth et al, 1986). Some inhibition of dopamine reuptake has been 
seen. Venlafaxine is administered as either immediate release (IR) or extended release (XR) 
tablets. XR formulation provides prolonged absorption of active drug in comparison with IR 
formulation, but total absorption of venlafaxine is the same (Entsuah et al, 1997). It has been 
demonstrated that XR gives less of the side-effects nausea and dizziness than IR (Entsuah et 
al, 1997). In addition, the XR formulation gives better patient compliance because it is taken 
once daily, in contrast to the IR formulation which is administered 2-3 times daily. Therefore, 
mainly XR tablets are in use today. 
 
Venlafaxine is metabolized mainly through CYP2D6 to the pharmacologically active 
metabolite O-desmetylvenlafaxine and to a minor degree to the pharmacologically inactive N-
desmethylvenlafaxine through CYP3A4, CYP2C9 and CYP2C19 (Figure 1.2) (Otton et al, 
1996).  In low venlafaxine concentrations in vitro, the contribution to the formation of O-
desmetylvenlafaxine by CYP2D6, CYP2C19 and CYP2C9 were estimated to be 89%, 10% 
and 1%, respectively, based on estimated Clint (Fogelman et al, 1999). For N-
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desmethylvenlafaxine, the contribution by CYP3A4, CYP2C19 and CYP2C9 are 36%, 33% 
and 31%, respectively (Fogelman et al, 1999). O-desmetylvenlafaxine and N-
desmethylvenlafaxine have been suggested to be metabolized further to the metabolite N, O-
didesmethylvenlafaxine (Muth et al, 1991) (Figure 1.2). O-desmethylvenlafaxine displays 
similar serotonin reuptake inhibition activity and two-fold higher noradrenalin reuptake 
inhibition than venlafaxine; while N-desmethylvenlafaxine and N, O-didesmetylvenlafaxine 
are pharmacologically inactive (Muth et al, 1991). In TDM, venlafaxine and O-
desmethylvenlafaxine are summarized, following Consensus Guidelines (Baumann et al, 
2004). The terminal half  life of venlafaxine and O-desmetylvenlafaxine are 5 hours and 11 
hours, respectively (Veefkind et al, 2000).  
 
Genetic polymorphism has been shown to be an important contribution to pharmacokinetic 
variability of venlafaxine. CYP2D6 PM have been shown to have an increased venlafaxine 
serum concentration in comparison to CYP2D6 EM (Veefkind et al, 2000, Fukuda et al, 
2000), while the sum of concentration venlafaxine plus O-desmetylvenlafaxine has been 
shown not to significantly differ between the different genotypes (Shams et al, 2006). The 
effect of heterozygote mutations in CYP2D6 on serum concentration of venlafaxine and 
metabolites is not known because the number of CYP2D6 HEM in these studies has been too 
low to study these patients separately (Veefkind et al, 2000, Fukuda et al, 2000).  
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Figure 1.2 Metabolism of venlafaxine. 
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1.7 Aims 
The aim of the present study was to investigate the importance of heterozygous mutations in 
CYP2D6 for serum concentrations of venlafaxine and risperidone (tablets and long-acting 
injection) and their main metabolites.  
 
In addition, analyses were done for: 
 The importance of heterozygous mutations in CYP2D6 for steady state serum concentrations 
of N-desmethylvenlafaxine.  
 The possible influence of mutations in CYP2C9 and CYP2C19 on the steady state serum 
concentration of venlafaxine. 
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2. METHODS 
 
2.1 Patient population and study design 
 
Data were collected from a TDM database at the department of Psychopharmacology at 
Diakonhjemmet Hospital. The patient samples were taken as a part of standard clinical 
follow-ups and routine control of drug treatment. For all the patients included in the analysis, 
CYP genotyping and serum analysis of risperidone and venlafaxine were performed in the 
period from January 2001 to August 2006. In order to be included in the study, the samples 
for serum analysis had to be drawn at steady state conditions. This implies that the patient 
must have been on stable dose of risperidone or venlafaxine, at least three days prior to blood 
sampling. For risperidone injection the requirement was at least three injections prior to 
sampling. In addition, samples must have been drawn 12-24 hours after previous oral dose, or 
13-15 days after previous injection of risperidone. Patients with a high probability of poor 
compliance were excluded from the study. Because of the possible drug-drug interactions 
samples were excluded from analysis when information on concomitant use of the CYP3A4 
inducing drug carbamazepine (Tegretol®) and the CYP2D6 inhibiting drug fluoxetine 
(Fontex®) was given on the request from. When more than one serum sample had been 
performed for the same patient, the sample nearest in time-relationship to the CYP-
genotyping was selected. Sex, age, dose and time between last drug intake and sample 
withdrawal were registered. For patients with samples on more than one dosage that fulfilled 
inclusion criteria, the mean serum concentration/dose ratio was calculated. The study was 
approved by the regional ethical committee.  
 
 2.2 Sample analysis 
 
2.2.1 Analysis of risperidone 
 
The development of the method has been performed at Psychopharmacologic Department at 
Diakonhjemmet Hospital and the method is used for the daily routine analysis. Briefly, 
purified samples (protein-precipitated with acetonitril) were injected on a Waters 2795 Liquid 
Chromatography and Micromass Quattro micro tandem detector (both from Milford, MA, 
USA). Risperidone and 9-hydroxyrisperidone were separated on a C18 analytical column 
protected by an ACE 3AQ guard column (both ACE 3AQ Advanced Chromatography 
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Technologies, Aberdeen, UK) by gradient elution (10%-80% acetonitril in 10 mmol/l 
ammoniumacetate buffer; pH=4.5). The retention times were 4.7 minutes (risperidone), 4.3 
minutes (9-hydroxyrisperidone) and 6.5 minutes (promazine, internal standard). Detection 
was performed with atmospheric pressure ionization after multiple reactions monitoring at 
transitions 411.2 → 191.1 for risperidone, 427.2 → 207.1 for 9-hydroxyrisperidone and 
285.2→212.1 for promazine. LOQs for risperidone and 9-hydroxyrisperidone were 1 nM. 
 
2.2.2 Analysis of venlafaxine 
 
The development of the method has been performed at Psychopharmacologic Department at 
Diakonhjemmet Hospital and the method is used for the daily routine analysis. Briefly, 
purified samples (protein-precipitated with acetonitril) were injected on a Waters 2795 Liquid 
Chromatography and Micromass Quattro micro tandem detector (both from Milford, MA, 
USA). The analytes were separated on a C18 analytical column (ACE 3AQ Advanced 
Chromatography Technologies, Aberdeen, UK) protected by a Sunfire C18 Guard column 
(Waters, Ireland) by gradient elution (24%-52% acetonitril in 10 mmol/l ammoniumacetate 
buffer; pH=4.5). The retention times were 2.3 minutes (O-desmethylvenlafaxine), 3.9 minutes 
(N-desmethylvenlafaxine), 4.2 minutes (venlafaxine) and 6 minutes (protriptyline, internal 
standard). Detection was performed with atmospheric pressure ionization after multiple 
reactions monitoring at transitions 278.15 → 260.15 for venlafaxine and 264.15 → 246.15 O-
desmethylvenlafaxine and N-desmethylvenlafaxine, and 264 →233.2 protriptyline. LOQs for 
venlafaxine, O-desmethylvenlafaxine and N-desmethylvenlafaxine were 10 nM. 
 
 
2.2.3 CYP-genotyping 
 
The CYP-genotyping is used in the daily routine analysis at Psychopharmacologic 
Department at Diakonhjemmet Hospital. Blood samples were collected in tubes containing 
EDTA as anticoagulant. Genomic DNA was isolated from leucocytes by E.Z.N.A® Blood 
DNA Kits II (Omega Bio-tek, Doraville, GA 30362, USA). All the polymerace chain reaction 
(PCR) amplification was carried out using Applied Biosystem 7500 Real-Time PCR 
instrument with Sequence Detection Software (SDS), Version 1.3 (Applied Biosystem, CA 
94404, USA). CYP2D6*2 (duplication) and CYP2D6*5 (deletion) mutations were determined 
by PCR reaction using a specific set of allele amplification primers (Schaeffler et al, 2003). 
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CYP2C9*2, *3, *5, CYP2C19*2, *3, *4, *5, CYP2D6*3, *4, *6, *7 and *8 mutations were 
determined by use of a long-range PCR amplifying the whole CYP2D6 gene, followed by 
multiplex allele specific PCR. The preamplication was diluted with water and used as 
template for two separate PCR reactions for the multiplex allele-specific PCR. The PCR 
reaction mix for each reaction was containing genomic DNA, specific primers, nucleoside 
triphosphates (dATP, dGTP, dCTP and dTTP), MgCl2 or Mg(OAc)2, buffer and ddH2O. 
AmpliTaq Gold DNA Polymerase was used in the CYP2C9, CYP2C19 and in the multiplex 
PCR. High fidelity DNA Polymerase was used in the CYP2D6*2 and *5 reactions, and the 
rTth DNA polymerase was used in the long-range PCR. The samples were separated by 
electrophoresis, and the fragments were compared with albumin as a molecular weight 
marker, an internal reference gene which was coamplified simultaneously in a single-tube 
biplex assay. Single nucleotide polymorphism (SNP) analysis positive controls representative 
of each genotype and negative or no template controls were included in each essay. For 
analysis of CYP2D6 copynumber, controls are patient samples with known genotype  normal 
control, duplication control and deletion control. 
 
2.3 Statistical methods 
 
All the statistical analysis was performed with SPSS® Software (SPSS Inc., Chicago, USA).  
Mann-Whitney test was used for comparing dose-adjusted serum concentrations of parent 
drugs, metabolites and metabolite/parent drug ratios between the different genotype 
groupings. p<0.05 was considered statistical significant.   
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3. RESULTS 
 
3.1 Risperidone tablets 
A total number of 68 patients fulfilled the inclusion criteria and were included in the analysis. 
Among these, 42 patients carried two functional CYP2D6 alleles and 23 patients carried one 
functional and one defect allele. The genotypes in this latter group were *1/*3 (n=1), *1/*4 
(n= 21) and *1/*5 (n=1). Among the rest, two patients carried two defect alleles, *3/*5* and 
4/*6, and one patient carried more than two functional alleles. 
 
Table 3.1 Demographic data of patients treated with risperidone tablets.  
 
CYP2D6   EM  HEM  PM  UM 
 
Total N (female/male)  42 (23/19) 23 (11/12)   2 (1/1)      1 (1/0) 
Age, years1   37 (15-80) 34 (22-57) 37 (25/48) 80 
Dose, mg/day1     4 (1-6)      4 (2-7)      3 (2-4)      3 
Sample withdrawal, hours1 13 (11-24) 14 (11-22) 18 (13-24) 13 
 
1Data are presented as median (range).    
 
There were no significant differences in demographic data between the EM and HEM groups 
(Table 3.1). Due to a low number of patients in the CYP2D6 PM and CYP2D6 UM groups, 
statistical testing was not considered meaningful for these groups. 
 
Table 3.2 Steady-state serum concentration-to-dose (C/D) ratios of risperidone, 9-hydroxyrisperidone and active 
moiety (sum of risperidone and 9-hydroxyrisperidone) and the ratio of 9-hydroxyrisperidone/risperidone in 
different CYP2D6 genotypes after administration of risperidone tablets.  
 
CYP2D6          EM      HEM      PM          UM 
 
Total N       42    23      2               1  
C/D risperidone, nM per mg1     0.9 (0-31.3)    7.9 (0-49.8)*     21.9 (20.3-23.5)         0.8 
C/D 9-hydroxyrisperidone, nM per mg1            10.9 (2.8-31)    9.3 (2.7-29)    6.5 (6.5-6.5)            23.9 
C/D active moiety, nM per mg1                13.6 (2.8-45)     16.3 (2.7-60.8)    28.4 (26.8-30)          24.7 
9-hydroxyrisperidone/risperidone1      7.2 (0-37.5)     1.1 (0-38.5)     0.3 (0.3-0.3)          31.9 
 
1Data are presented as median (range). 
* Significant difference (p<0.01) CYP2D6 HEM versus CYP2D6 EM. 
 
The steady-state serum concentrations of risperidone ranged from <1 to 199 nM and those of 
9-hydroxyrisperidone from 6 to 113 nM (Table 3.2). Eight patients had steady state serum 
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concentrations under LOQ for risperidone. As the daily dose of risperidone varied between 1 
and 7 mg, the measured concentrations of risperidone and 9-hydroxyrisperidone were 
corrected for the dose (concentration/dose; nM per mg). The C/D ratio of risperidone was 
eight-fold higher in the CYP2D6 HEM group than in the CYP2D6 EM group (p<0.01) (Table 
3.2, figure 3.1 a). The corresponding values for 9-hydroxyrisperidone did not show statistical 
difference between the groups; however median in the CYP2D6 HEM group tended to be 
lower in the CYP2D6 EM group (Figure 3.1 b). There were no significant differences in C/D 
ratio of the active moiety (sum of risperidone plus 9-hydroxyrisperidone) between the 
CYP2D6 EM and CYP2D6 HEM groups (Figure 3.1 c). No significant differences were 
found in 9-hydroxyrisperidone/risperidone ratio between the CYP2D6 EM and CYP2D6 
HEM groups, however median in the HEM group appeared to be lower than the CYP2D6 EM 
group (Table 3.2, figure 3.1 d). 
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(c) risperidone plus 9-OH risperidone
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Figure 3.1 Relationship between CYP2D6 genotype and C/D ratio of (a) risperidone, (b) 9-hydroxyrisperidone, 
(c) risperidone plus 9-hydroxyrisperidone and (d) metabolic ratio (9-hydroxyrisperidone/risperidone) after 
administration of risperidone tablets.  
 
3.2 Risperidone long-acting injection 
 
A total number of 50 patients were included in the study. Among these, 32 patients carried 
two functional CYP2D6 alleles and 12 patients carried one functional allele and one defect 
allele, *1/*4. Among the rest, four patients carried two defect CYP2D6 alleles, *3/*4 (n=2) 
and *4/*5 (n=2) and two patients carried more than two functional CYP2D6 alleles.  
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Table 3.3 Demographic data of patients treated with risperidone long-acting injection.  
 
CYP2D6   EM  HEM  PM  UM 
 
Total N (female/male)  32 (12/20) 12 (4/8)      4 (1/3)      2 (2/0) 
Age, years1   38 (17-63) 29 (20-62) 34 (27/53) 65 (48-81) 
Dose, mg/two weeks1  44 (25-75) 38 (25-50)  53 (50-75)   38 (25-50) 
Sample withdrawal, days1  14 (13-16) 14 (13-15) 14 (13-14) 13 (13-13) 
 
1Data are presented as median (range). 
 
There were no significant differences in distribution of sex, age and time-interval between last 
injection and sample withdrawal between CYP2D6 EM and CYP2D6 HEM groups. However, 
the CYP2D6 EM group received significantly higher doses of risperidone than the CYP2D6 
HEM group (p=0.03).  Due to a low number of patients in the CYP2D6 PM and CYP2D6 UM 
groups, statistical testing was not considered meaningful for these groups. 
 
Table 3.4 Steady-state serum concentration-to-dose (C/D) ratios of risperidone, 9-hydroxyrisperidone and active 
moiety (sum of risperidone and 9-hydroxyrisperidone) and ratio of 9-hydroxyrisperidone/risperidone in different 
CYP2D6 genotypes after administration of risperidone long-acting injection.  
 
CYP2D6    EM  HEM  PM  UM 
 
Total N      32   12    4            2  
C/D risperidone, nM per mg1,2       0.3 (0.1-1.1)   0.3 (0.1-2.7)       0.8 (0.4-1.2)    0.3 (0.2-0.4) 
C/D 9-hydroxyrisperidone, nM per mg1,2           0.9 (0.2-1.7)   0.7 (0.1-1.4)        0.1 (0.1-0.2)   1.2 (0.2-2.2) 
C/D Sum active moiety, nM per mg1,2     1.2 (0.5-2.2)       1.2 (0.4-3.4)       1 (0.5-1.3)      1.5 (0.5-5.4) 
9-hydroxyrisperidone /risperidone1      3.2 (0.2-5.5)   1.4 (0.3-4.1)*   0.2 (0-0.3)      3.2 (0.5-5.4) 
 
1Data are presented as median (range). 
2mg/two weeks 
* Significant difference (p<0.03) CYP2D6 HEM versus CYP2D6 EM genotype. 
 
The steady-state serum concentrations of risperidone ranged from 5 nM to 89 nM and those of 
9-hydroxyrisperidone from 11 nM to 86 nM (Table 3.4). As the risperidone injections are 
administered every two weeks, the measured concentrations of risperidone were corrected for 
the dose/two weeks in the same manner as risperidone tablets were corrected for dose/day.  
 
The 9-hydroxyrisperidone/risperidone ratio was a significantly higher in the CYP2D6 EM 
group compared with the CYP2D6 HEM group (p<0.03) (Figure 3.2 d). The C/D ratio of 
risperidone was not significantly different between the CYP2D6 genotypes (Figure 3.2 a). No 
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significant differences in the C/D ratios of 9-hydroxyrisperidone were found, however, the 
median in the CYP2D6 EM group seemed higher than median in the CYP2D6 HEM group 
(Figure 3.2 b). There was no significant difference in C/D ratio of active moiety between the 
CYP2D6 EM and CYP2D6 HEM (Figure 3.2 c).  
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(c) risperidone plus 9-OH risperidone
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Figure 3.2 Relationship between CYP2D6 genotype and C/D ratio of (a) risperidone, (b) 9-hydroxyrisperidone, 
(c) risperidone plus 9-hydroxyrisperidone and (d) metabolic ratio (9-hydroxyrisperidone /risperidone) after 
administration of risperidone long-acting injection. 
 
 
 
3.4 Venlafaxine 
 
A total number of 98 patients were included in the analysis. Among these, 52 patients carried 
two functional CYP2D6 alleles and 41 patients carried one functional and one defect allele. 
The genotypes in this latter group were *1/*3 (n=1), *1/*4 (n= 34), *1/*5 (n=5) and *1/*6 
(n=1). Among the rest, one patient carried two defect alleles, *4/*5 and four patient carried 
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more than two functional alleles. Furthermore, for 19 of the 98 patients the N-
desmethylvenlafaxine concentration was determined. Among these, 13 patients carried two 
functional CYP2D6 alleles, six patients carried one functional and one defect allele, *1/*4.  
 
Table 3.5 Demographic data of patients treated with venlafaxine tablets.  
 
CYP2D6   EM  HEM  PM  UM 
 
Total N (female/male)  52 (31/21) 41 (26/15)    1 (1/0)                 4 (3/1) 
Age, years1   39 (13-80) 39 (17-69)   45   41 (32-44) 
Dose, mg/day1           150 (37.5-375)   150 (37.5-375)  300                113 (75-300) 
Sample withdrawal, hours1 18 (11-25) 16 (11-24)   20                12 (12-13) 
Number of CYP2C9 EM  30  28      0                         2 
Number of CYP2C9 HEM 17    6      1                         1 
Number of CYP2C9 PM   2    0      0     1 
Number of unknown CYP2C9  3    7      0     1 
Number of CYP2C19 EM  32  21      1                         3 
Number of CYP2C19 HEM 18  13      0                         0 
Number of unknown CYP2C19  3    7      0     1 
 
1Data are presented as median (range). 
 
There were no significant differences in demographic data between the CYP2D6 EM and 
HEM groups (Table 3.5). Due to a low number of patients in the CYP2D6 PM and CYP2D6 
UM groups, statistical testing was not considered meaningful for these groups. 
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Table 3.6 Steady-state serum concentrationto-dose (C/D) ratios of venlafaxine, O-desmethylvenlafaxine, N-
desmethylvenlafaxine and active moiety (sum of venlafaxine and O-desmethylvenlafaxine) and ratios of O-
desmethylvenlafaxine/venlafaxine and N-desmethylvenlafaxine/venlafaxine in different CYP2D6 genotypes.  
 
 
CYP2D6         EM     HEM    PM          UM 
 
Total N         52     41       1      4 
C/D venlafaxine, nM per mg1       1.5 (0.2-9.1)     1.9 (0.3-20.0)        2.2            3.6 (0.4-6.2) 
C/D O-desmethylvenlafaxine, nM per mg1        3.9 (1.0-10.7)       3.1 (0.1-7.7)*        3.2           5.3 (2.3-8.9) 
C/D Sum active moiety, nM per  mg1       5.3 (1.2-16.9)       5.2 (1.5-20.1)        5.4          9.4 (5.8-11.1) 
O-desmethylvenlafaxine/venlafaxine1          3.2 (0.3-15.6)        1.6 (0.1-8.5)**     1.5          3.6 (0.4-13.5) 
C/D N-desmethylvenlafaxine, nM per mg1, 2            0.2 (0-1.8)       1.9 (0.2-3.7)***  
N-desmethylvenlafaxine/venlafaxine1,2          0.2 (0-0.7)      0.5 (0.2-1.5) 
 
1Data are presented as median (range). 
2The serum concentration of N-desmethylvenlafaxine was determined for 19 of the 98 patients. 
*    Significant difference (p<0.02) CYP2D6 EM versus CYP2D6 HEM genotype. 
**  Significant difference (p<0.01) CYP2D6 EM versus CYP2D6 HEM genotype. 
*** Significant difference (p<0.01) CYP2D6 EM versus CYP2D6 HEM genotype. 
 
The steady-state serum concentrations of venlafaxine ranged from 21 nM to 2996 nM, those 
of O-desmethylvenlafaxine from 22 nM to 2040 nM and those of N-desmethylvenlafaxine 
from <10 nM to 998 nM. Three patients had steady state serum concentrations under LOQ for 
N-desmethylvenlafaxine. Due to a wide range of daily doses (37.5 mg to 375 mg), measured 
concentrations were corrected for the doses (Table 3.6).  
 
The C/D ratio of O-desmethylvenlafaxine was significantly higher in the CYP2D6 EM group 
compared with the CYP2D6 HEM group (p<0.02), while the C/D ratios of venlafaxine did not 
differ significantly between the CYP2D6 EM and CYP2D6 HEM groups (Figure 3.3 a and 
3.3 b). Also, the O-desmethylvenlafaxine/venlafaxine ratio was significantly higher in 
CYP2D6 EM compared with the CYP2D6 HEM group (p<0.01) (Figure 3.3 d). The C/D ratio 
of active moiety (venlafaxine plus O-desmethylvenlafaxine) did not differ significantly 
between the CYP2D6 EM and CYP2D6 HEM group (Figure 3.3 c).  
 
The N-desmethylvenlafaxine C/D ratio was significantly higher (9 fold higher) between in the 
CYP2D6 HEM group compared to the CYP2D6 EM group (p<0.01). Nevertheless, the six 
patients in the HEM group were separated into two clusters (Figure 3.4 a). There were no 
significant differences in N-desmethylvenlafaxine/venlafaxine ratio between the two groups 
(Figure 3.4 b).  
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Figure 3.3 Relationship between the CYP2D6 genotype and C/D ratio of (a) venlafaxine, (b) O-
desmethylvenlafaxine, (c) venlafaxine plus O-desmethylvenlafaxine and (d) metabolic ratio (O-
desmethylvenlafaxine/venlafaxine).  
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Figure 3.4 Relationship between the CYP2D6 genotype and (a) C/D ratio N-desmethylvenlafaxine and (b) 
metabolic ratio (N-desmethylvenlafaxine/venlafaxine). 
 
A total number of 60 patients carried two functional CYP2C9 alleles and 25 patients carried 
one functional and one impaired CYP2C9 allele. The genotypes in this latter group were 
*1/*2 (n=14), CYP2C9*1/*3 (n=15). Among the rest, two patient carried two impaired 
CYP2C9 alleles, *2/*3. A total number of 57 patients carried two functional CYP2C19 alleles 
and 30 patients carried one functional and one defect CYP2C19 allele. The genotype in this 
latter group were *1/*2 (n=31). For both CYP2C9 and CYP2C19 there were 11 patients that 
were not genotyped. Effect of mutations in CYP2C9 and CYP2C19 was investigated in 
patients being either CYP2D6 EM or CYP2D6 HEM. There was a significant difference 
(p<0.05) in C/D ratio of active moiety (venlafaxine plus O-desmethylvenlafaxine), where 
patients being a combination of CYP2C9 HEM and CYP2D6 EM (n=17, median=5.6) had 
21% higher median than patients being CYP2C9 EM and CYP2D6 EM (n=30, median=4.6). 
Despite the observed difference, patients with different mutations in CYP2C9 were included 
in the study because there was about the same frequency of CYP2C9 mutations in the 
CYP2D6 EM and HEM groups. Variation in CYP2C9 genotype therefore probably does not 
affect the results of the CYP2D6 analysis. 
 
Of the 98 patients included in the study, six persons were receiving venlafaxine immediate 
release (IR) tablets, two of the patients were CYP2D6 EM and four of the patients were 
CYP2D6 HEM. The rest of the patients were receiving extended release (XR) tablets. Data of 
patients on IR tablets were plotted in the same plots as data of patients on XR tablets. The 
data of IR tablets were evenly distributed among the data of XR tablets and did not differ 
from the data for the IR tablets, therefore all data were analyzed together. 
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4. DISCUSSION 
 
4.1 Risperidone tablets and risperidone long-acting injection 
 
This is the first analysis to investigate the influence of CYP2D6 genotype on serum 
concentration for risperidone long acting injection. A significant influence of CYP2D6 
genotype for serum concentration of risperidone tablets has been previously shown (Scordo et 
al, 1999). An analysis comparing oral and long-acting risperidone showed that patients 
receiving oral risperidone had about four-fold higher plasma metabolite/drug ratio compared 
to patients receiving the new depot formulation (Nesvåg et al, 2006). The lower level of 9-
hydroxyrisperidone in the depot group may be a result of reduced first-pass metabolism 
(Nesvåg et al, 2006). Because the influence of CYP3A4 and CYP2D6 probably are different 
for the two formulations, it was of interest to see whether CYP2D6 polymorphism has 
different impact on the two formulations.    
 
In patients medicated with risperidone tablets, the parent compound risperidone was over 
eight times higher in CYP2D6 HEM compared to CYP2D6 EM. This was not observed in a 
previous study where CYP2D6 PM had significantly higher risperidone than the other 
genotypes, but there were no significant differences for the CYP2D6 HEM patients (Scordo et 
al, 2006). This difference might be a result of a higher number of patients in our analysis 
(n=23 versus n=15). In spite of the differences in serum concentrations of risperidone between 
CYP2D6 EM and HEM, there are no significant differences between the two genotypes in the 
active moiety (sum of risperidone and 9-hydroxyrisperidone). This is probably due to 
increased elimination of risperidone through CYP3A4, the alternative metabolism pathway of 
risperidone (Figure 1.1). In contrast to the study by Scordo and co-workers where 
significantly higher risperidone/9-hydroxy risperidone ratios were observed in CYP2D6 HEM 
and PM versus CYP2D6 EM, no difference in this ratio was observed in the present analysis. 
This is probably due to a large variability in our data (Figure 3.1 d). Probable causes of this 
variability include possible partial non-compliant patients, drug intake that we are unaware of, 
for instance CYP3A4 inducers carbamazepine or St. Johns wort. In addition, the patients 
might be misclassified as HEM as only 30% of UM can be detected by genotyping, or they 
might have rare mutations that was not detected in the genotyping. The terminal half-life of 
risperidone and 9-hydroxyrisperidone are about 6-7 hours and about 24 hours, respectively. 
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The serum samples have been withdrawn between 12 and 24 hours and the samples 
withdrawn closer to 24 hours therefore have higher 9-hydroxyrisperidone/risperidone ratio 
than the samples withdrawn closer to 12 hours.  
 
For risperidone long-acting injection, the 9-hydroxyrisperidone/risperidone ratio was over 
twice as high for CYP2D6 EM patients as for HEM patients. In contrast to risperidone tablets 
there was no difference in serum concentration of risperidone for risperidone long-acting 
injection. However, the differences between risperidone long-acting injection and risperidone 
tablets might be due to a difference in the influence of CYP3A4. As there is more CYP3A4 
than CYP2D6 in the intestine (Lin, Lu, 2001), the difference in administration route may 
result in different relative significance of the two enzymes for the two formulations. 
 
Studies indicate that P-glycoprotein (P-gp) in the blood-brain-barrier (BBB) reduces the brain 
concentration of risperidone and 9-hydroxyrisperidone by limiting their CNS-access 
(Nakagami et al, 2005, Wang et al, 2004). 9-hydroxyrisperidone has been shown to be more 
effectively transported by P-gp than risperidone through the BBB, as the ratio of brain to 
plasma of 9-hydroxyrisperidone in P-gp knockout mouse was 2.4 fold higher than that of 
risperidone (Wang et al, 2004, Doran et al, 2005). The distribution of 9-hydroxyrisperidone to 
the different brain-regions, including frontal cortex and striatum, has also been shown to be 
more limited than for risperidone itself (van Beijsterveldt et al, 1994). Patients with higher 
serum levels of risperidone, such as CYP2D6 HEM patients, will therefore probably obtain 
higher active brain concentrations compared to CYP2D6 EM patients. This possible 
difference in concentration at site of action will probably also cause a difference in effect. 
 
The CYP2D6 EM patients in our analysis received about 15% higher doses of risperidone 
long-acting injection than the CYP2D6 HEM patients. This could be due to a better toleration 
of higher doses in CYP2D6 EM compared to HEM. This is in accordance with an elevated 
prevalence of adverse-drug reactions and discontinuation in CYP2D6 PM patients (de Leon et 
al, 2005). This further supports our hypothesis that a change of risperidone makes a difference 
for effect/side-effect, even though sum of risperidone plus 9-hydroxyrisperidone and/or the 
ratio not have changed.  
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4.2 Venlafaxine  
 
In the present analysis, the level of O-desmethylvenlafaxine was about 25% higher in 
CYP2D6 EM than in HEM. This difference was not observed by Shams and co-workers, 
probably due to a low number of patients (n=5) compared to our analysis (n=41). The level of 
venlafaxine did not differ significantly between CYP2D6 EM and HEM. The lack of increase 
in venlafaxine could be caused by increased formation of N-desmethylvenlafaxine through 
CYP3A4 when CYP2D6 metabolism is impaired (Figure 1.1). This is supported by 
significantly higher serum concentrations in N-desmethylvenlafaxine in CYP2D6 HEM 
versus EM patients shown in the present analysis (Figure 4.1). Also, there seems to be 
corresponding lower O-desmethylvenlafaxine levels in patients with high N-
desmethylvenlafaxine and vice versa (Figure 4.1). It would have been useful with more 
patients in this analysis, but analysis of N-desmethylvenlafaxine has only been measured at 
Department of Psychopharmacology, Diakonhjemmet hospital since March 2006.  
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Figure 4.1 -dose ratios of O-desmethylvenlafaxine and N-desmethylvenlafaxine 
In (■) CYP2D6 extensive metabolizers (n=13) and (□) CYP2D6 heterozygous metabolizers (n=6).  
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In spite of the differences in C/D ratio of O-desmethylvenlafaxine between CYP2D6 EM and 
HEM, there were no significant differences between the genotypes in the active moiety 
(venlafaxine plus O-desmethylvenlafaxine). The ratio of O-desmethylvenlafaxine/venlafaxine 
was, however twice as high in CYP2D6 EM patients as in CYP2D6 HEM patients. O-
desmethylvenlafaxine displays similar serotonin reuptake inhibition activity and two-fold 
higher noradrenalin reuptake inhibition than venlafaxine (Muth et al, 1986) and a change in 
the ratio of metabolites might therefore also result in a change in effect. It has been observed 
that side effects of venlafaxine like nausea, vomiting and diarrhea are increased in CYP2D6 
PM compared to EM (Shams et al, 2006).  Correspondingly, the risk of side effects increases 
with decreasing ratio of O-desmethylvenlafaxine/venlafaxine (Shams et al, 2006). The authors 
blamed this effect on the increased levels of parent compound venlafaxine (Shams et al, 
2006). However both venlafaxine and N-desmethylvenlafaxine are increased and both 
substances increase in the same patient category that has the observed side-effects. The side-
effects might therefore just as well be due to the increased level of N-desmethylvenlafaxine 
that also appears in patients with reduced CYP2D6 capacity. The percent increase in serum 
C/D ratio for CYP2D6 HEM patients compared to CYP2D6 EM patients is higher for N-
desmethylvenlafaxine (850% higher levels of N-desmethylvenlafaxine in CYP2D6 HEM 
compared to CYP2D6 EM ) than for venlafaxine (26% higher levels of venlafaxine in 
CYP2D6 HEM than CYP2D6 EM). A further complicating factor is that venlafaxine is a 
chiral drug, and that CYP2D6 displays marked stereoselectivity towards the (R)-enantiomer. 
This could have clinical consequences and thus underlie the observed differences in the 
occurrence of side effects in CYP2D6 PM and EM (Eap et al, 2003). This issue needs further 
investigation, and from current data available it is not possible to point to which of the 
compounds that causes side-effects. 
  
It was expected that a possible influence of CYP2C9 and CYP2C19 genotypes on the serum 
concentration of venlafaxine would be best uncovered by investigating the group of patients 
that were CYP2D6 HEM because the main metabolism pathway is reduced in these patients. 
Surprisingly, there was a 21% higher active moiety (sum of venlafaxine and O-
desmethylvenlafaxine) in the CYP2D6 EM patient group with a higher median of CYP2C9 
EM than the median of 2C9 HEM. The observed significant influence of mutations in 
CYP2C9 in CYP2D6 EM patients and not in CYP2D6 HEM patients can not be explained by 
current available data/literature, and more patients are needed to investigate the possible 
influence of genotype for serum concentration on these enzymes separately. 
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4.3 Clinical implications 
 
In common for risperidone and venlafaxine is that the active moiety not is changed in 
CYP2D6 HEM versus EM, but there are changes in the ratios of parent drug and metabolite. 
Today, the plasma concentration sum of drug and active metabolite is used in TDM practice 
for both these drugs (Baumann et al, 2004). Wanted and unwanted drug effects depend on the 
concentration on the site of action. The brain is not accessible to drug monitoring, but plasma 
concentrations are thought to reflect brain concentrations. However, animal studies have 
shown variable brain distribution of parent compounds and active metabolites for both 
risperidone and venlafaxine.  
 
Serum/plasma average of 9-hydroxyrisperidone is higher than the concentrations of 
risperidone itself, 90-95% of the drug is present as 9-hydroxyrisperidone in plasma (Olesen et 
al, 1998, Riedel et al, 2005). Animal studies have shown at least five-fold more extensive 
distribution of risperidone and at least two-fold more extensive distribution of venlafaxine in 
brain compared to their active metabolites (Doran et al, 2005, Uhr et al, 2003, Wang et al, 
2004). The pharmacological activity of 9-hydroxyrisperidone is approximately 70% 
comparable to risperidone in respect to activity (Van Bejsterveld et al, 1994). O-
desmethylvenlafaxine displays similar serotonin reuptake inhibition activity and two-fold 
higher noradrenalin reuptake inhibition than venlafaxine (Muth et al, 1986). This indicates 
that 9-hydroxyrisperidone and O-desmethylvenlafaxine contributes to the in vivo activity of 
the drugs, but to a smaller extent than would be predicted from plasma levels. Whether these 
differences in distribution is present in humans remains to be investigated, but if so, variable 
plasma metabolite/parent drug ratios caused by genetic polymorphism of drug metabolizing 
enzymes, metabolic drug-drug interactions or different administration routes could reflect 
different active concentrations in the brain, despite similar total concentrations of drug and 
metabolite in plasma. A change in metabolite ratio for risperidone and venlafaxine might 
therefore contribute to variation in effect/side-effect of the drugs. 
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4.4 Strengths and weaknesses in the studies 
 
This analysis, with data from a naturalistic clinical setting, includes a relatively high number 
of patients. Age and sex are equally distributed between the CYP2D6 EM and HEM, and 
differences in serum concentrations are therefore most likely due to differences in genotypes.  
 
In this analysis the C/D ratio has been used in order to compare serum concentrations for 
patients on different drug dosages. This dose-corrected serum concentration is a presumption 
of that the drugs follows linear kinetics, which is not necessarily correct. For risperidone long-
acting injection, there was a significant difference in dosage between the CYP2D6 EM versus 
HEM group, which is a possible source of error. 
 
These analyses are based on information given from the prescribing clinician and there is no 
direct contact with the patients. The patients might therefore be medicated with drugs that we 
are unaware of, for instance CYP2D6 inhibitors or CYP3A4 inducers or inhibitors.  
 
Patients might be classified into wrong genotype groups because of undetected mutations. 
CYP2D6*9, *10 and *17 are not genotyped in this analysis. Studies have indicated a 
CYP2D6*9 allele frequency of 1-2% in Caucasians and CYP2D6*10 allele frequency of <2% 
in Caucasians (Bradford, 2002). In addition, CYP2D6*10 mutated alleles are more common 
in Asians immigrants, which not are excluded from this study, with an allele frequency of 
about 41% (Bradford, 2002). The CYP2D6*17 is very rare in Caucasians (Bradford, 2002) but 
is a mutation common among Africans and African-Americans with a frequency of about 
24% and might appear in African and African-American immigrants analyzed in this study. 
Another mutation not genotyped in this analysis is CYP2C19*17. This mutation increases 
metabolism of drugs metabolized by CYP2C19 and have a frequency of approximately 18% 
in Caucasians (Sim et al, 2005). 
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5. Conclusion 
 
Common for risperidone and venlafaxine is that even though the sum of the active moiety not 
is changed, the ratio of metabolite/ parent drug is. It is the sum of the active moiety that is 
determined in TDM, and patients are therefore treated equally because the sum will be the 
same independent of genotype. This is a problem if there is a difference in effect/adverse drug 
reactions mediated by parent drug and metabolite. A changed metabolite ratio might therefore 
be considered as a possible cause of unexpected clinical response. More knowledge of 
possible differences for the metabolite versus parent drug in for instance receptor affinity 
and/or distribution is necessary to optimize the treatment with these drugs in relation to the 
patient genotype.  
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